Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891454111> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2891454111 endingPage "e14059" @default.
- W2891454111 startingPage "e14059" @default.
- W2891454111 abstract "e14059 Background: The 3 rd generation TKI is still not available for Chinese NSCLC patients with EGFR-mutant who develop acquired resistance following treatment with 1 st EGFR tyrosine kinase inhibitors (EGFR-TKIs). Apatinib, a novel small molecule TKI targeted VEGFR2, recommended as third-line treatment for metastatic gastric cancer patients, might be used as an alternative strategy for these patients. This study is an initial clinical experience about Apatinib for EGFR-mutant NSCLC patients with 1 st TKI resistance. Methods: Eight patients pathological diagnosed as adenocarcinoma with EGFR mutant were enrolled between January, 2016 and January, 2017. All patients had undergone TKI treatment and disease progression. They had an ECOG performance status (PS) of 0–1. 250 mg-500mg/day of Apatinib was continuously administered for two months, during which we observed the curative effect and adverse events closely. Informed consent was obtained from each patient before enrollment. Results: Computed tomography (CT) scan evaluation revealed that partial response (PR) occurred in 25% (2/8) patients and other 75% (6/8) showed stable disease (SD). There was no progressive disease (PD) occurred. Hypertension is one of the most frequent adverse reactions, which appeared in 50% (4/8) patients who were getting to be normal under antihypertensive agent. Others like hand-foot syndrome, anergy and temple elevated urine protein also appeared and could be better controlled. Conclusions: Apatinib is a safe and effective oral targeted drug on EGFR-mutant NSCLC patients with TKI resistance. It could provide a new therapy strategy for them before taking osimertinib. To further investigate the role of Apatinib in drug resistant EGFR-mutant NSCLC, large sample and additional clinical trials are needed. Table1. Clinicopathologic Characteristics of Patients. [Table: see text]" @default.
- W2891454111 created "2018-09-27" @default.
- W2891454111 creator A5008508108 @default.
- W2891454111 creator A5017316066 @default.
- W2891454111 creator A5022486856 @default.
- W2891454111 creator A5028674351 @default.
- W2891454111 creator A5048800314 @default.
- W2891454111 creator A5056036725 @default.
- W2891454111 creator A5058382693 @default.
- W2891454111 creator A5070036406 @default.
- W2891454111 creator A5070549294 @default.
- W2891454111 date "2017-05-20" @default.
- W2891454111 modified "2023-09-24" @default.
- W2891454111 title "Apatinib for EGFR-TKIs resistant NSCLC patients: Initial clinical experience." @default.
- W2891454111 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e14059" @default.
- W2891454111 hasPublicationYear "2017" @default.
- W2891454111 type Work @default.
- W2891454111 sameAs 2891454111 @default.
- W2891454111 citedByCount "0" @default.
- W2891454111 crossrefType "journal-article" @default.
- W2891454111 hasAuthorship W2891454111A5008508108 @default.
- W2891454111 hasAuthorship W2891454111A5017316066 @default.
- W2891454111 hasAuthorship W2891454111A5022486856 @default.
- W2891454111 hasAuthorship W2891454111A5028674351 @default.
- W2891454111 hasAuthorship W2891454111A5048800314 @default.
- W2891454111 hasAuthorship W2891454111A5056036725 @default.
- W2891454111 hasAuthorship W2891454111A5058382693 @default.
- W2891454111 hasAuthorship W2891454111A5070036406 @default.
- W2891454111 hasAuthorship W2891454111A5070549294 @default.
- W2891454111 hasConcept C121608353 @default.
- W2891454111 hasConcept C126322002 @default.
- W2891454111 hasConcept C143998085 @default.
- W2891454111 hasConcept C197934379 @default.
- W2891454111 hasConcept C2775832928 @default.
- W2891454111 hasConcept C2777626846 @default.
- W2891454111 hasConcept C2778087573 @default.
- W2891454111 hasConcept C2778820342 @default.
- W2891454111 hasConcept C2778822529 @default.
- W2891454111 hasConcept C2779134260 @default.
- W2891454111 hasConcept C2779438470 @default.
- W2891454111 hasConcept C2780668389 @default.
- W2891454111 hasConcept C2781230642 @default.
- W2891454111 hasConcept C71924100 @default.
- W2891454111 hasConcept C90924648 @default.
- W2891454111 hasConceptScore W2891454111C121608353 @default.
- W2891454111 hasConceptScore W2891454111C126322002 @default.
- W2891454111 hasConceptScore W2891454111C143998085 @default.
- W2891454111 hasConceptScore W2891454111C197934379 @default.
- W2891454111 hasConceptScore W2891454111C2775832928 @default.
- W2891454111 hasConceptScore W2891454111C2777626846 @default.
- W2891454111 hasConceptScore W2891454111C2778087573 @default.
- W2891454111 hasConceptScore W2891454111C2778820342 @default.
- W2891454111 hasConceptScore W2891454111C2778822529 @default.
- W2891454111 hasConceptScore W2891454111C2779134260 @default.
- W2891454111 hasConceptScore W2891454111C2779438470 @default.
- W2891454111 hasConceptScore W2891454111C2780668389 @default.
- W2891454111 hasConceptScore W2891454111C2781230642 @default.
- W2891454111 hasConceptScore W2891454111C71924100 @default.
- W2891454111 hasConceptScore W2891454111C90924648 @default.
- W2891454111 hasIssue "15_suppl" @default.
- W2891454111 hasLocation W28914541111 @default.
- W2891454111 hasOpenAccess W2891454111 @default.
- W2891454111 hasPrimaryLocation W28914541111 @default.
- W2891454111 hasRelatedWork W2081703574 @default.
- W2891454111 hasRelatedWork W2283064216 @default.
- W2891454111 hasRelatedWork W2561563892 @default.
- W2891454111 hasRelatedWork W2772987978 @default.
- W2891454111 hasRelatedWork W2791249304 @default.
- W2891454111 hasRelatedWork W2967537257 @default.
- W2891454111 hasRelatedWork W2982295426 @default.
- W2891454111 hasRelatedWork W3083211100 @default.
- W2891454111 hasRelatedWork W3159453953 @default.
- W2891454111 hasRelatedWork W4292449075 @default.
- W2891454111 hasVolume "35" @default.
- W2891454111 isParatext "false" @default.
- W2891454111 isRetracted "false" @default.
- W2891454111 magId "2891454111" @default.
- W2891454111 workType "article" @default.